secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ainos, Inc. (AIMD)
CIK:        0001014763
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001493152-24-018884
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ainos Q1 revenue down 58% YoY to $20.7K; net loss widens to $3.3M; secures $9M convertible note
--------------------------------------------------------------------------------

- Revenue of $20,729 in Q1 2024, down 58% from $49,164 in Q1 2023, due to pivot from COVID-19 test kits.
- Net loss attributable to common stockholders was $3.3M, compared to $2.5M in prior year.
- Cash and cash equivalents $1.03M as of Mar 31, 2024, down from $1.89M at Dec 31, 2023.
- Raised $9M convertible note post-quarter (6% interest, convertible at $4.50/sh) from existing shareholder.
- Submitted clinical hold response to FDA for VELDONA Phase II trial for mild COVID-19.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1014763/000149315224018884/0001493152-24-018884-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1014763/000149315224018884/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-018884

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer